329 related articles for article (PubMed ID: 18256683)
1. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.
Balasubramanian S; Ramos J; Luo W; Sirisawad M; Verner E; Buggy JJ
Leukemia; 2008 May; 22(5):1026-34. PubMed ID: 18256683
[TBL] [Abstract][Full Text] [Related]
2. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
Suzuki T; Ota Y; Ri M; Bando M; Gotoh A; Itoh Y; Tsumoto H; Tatum PR; Mizukami T; Nakagawa H; Iida S; Ueda R; Shirahige K; Miyata N
J Med Chem; 2012 Nov; 55(22):9562-75. PubMed ID: 23116147
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
Watters JM; Wright G; Smith MA; Shah B; Wright KL
Biochem Biophys Res Commun; 2021 Jan; 534():773-779. PubMed ID: 33190829
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Lopez G; Pollock RE
Methods Mol Biol; 2017; 1510():365-374. PubMed ID: 27761835
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Duan H; Heckman CA; Boxer LM
Mol Cell Biol; 2005 Mar; 25(5):1608-19. PubMed ID: 15713621
[TBL] [Abstract][Full Text] [Related]
7. Potent and Selective Non-hydroxamate Histone Deacetylase 8 Inhibitors.
Kleinschek A; Meyners C; Digiorgio E; Brancolini C; Meyer-Almes FJ
ChemMedChem; 2016 Dec; 11(23):2598-2606. PubMed ID: 27860422
[TBL] [Abstract][Full Text] [Related]
8. HDAC8-mediated epigenetic reprogramming plays a key role in resistance to anthrax lethal toxin-induced pyroptosis in macrophages.
Ha SD; Han CY; Reid C; Kim SO
J Immunol; 2014 Aug; 193(3):1333-43. PubMed ID: 24973453
[TBL] [Abstract][Full Text] [Related]
9. HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).
Lopez G; Bill KL; Bid HK; Braggio D; Constantino D; Prudner B; Zewdu A; Batte K; Lev D; Pollock RE
PLoS One; 2015; 10(7):e0133302. PubMed ID: 26200462
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
[TBL] [Abstract][Full Text] [Related]
11. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
[TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Banerjee S; Adhikari N; Amin SA; Jha T
Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
[TBL] [Abstract][Full Text] [Related]
15. Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy.
Spreafico M; Cafora M; Bragato C; Capitanio D; Marasca F; Bodega B; De Palma C; Mora M; Gelfi C; Marozzi A; Pistocchi A
Pharmacol Res; 2021 Aug; 170():105750. PubMed ID: 34214631
[TBL] [Abstract][Full Text] [Related]
16. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
[TBL] [Abstract][Full Text] [Related]
17. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
[TBL] [Abstract][Full Text] [Related]
19. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase 8 in neuroblastoma tumorigenesis.
Oehme I; Deubzer HE; Wegener D; Pickert D; Linke JP; Hero B; Kopp-Schneider A; Westermann F; Ulrich SM; von Deimling A; Fischer M; Witt O
Clin Cancer Res; 2009 Jan; 15(1):91-9. PubMed ID: 19118036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]